Ultimate magazine theme for WordPress.

Virpax Pharmaceuticals (VRPX) – New Developments in Pain Management NobleCon Online Investor Event


Virpax is developing branded product candidates for non-addictive pain management and neurological disorders using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval of its three patented drug delivery platforms. Epoladerm™ is a topical diclofenac spray film formulation being developed to manage osteoarthritis pain. Probudur™ is a single injection long-acting liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta™ is an intranasal Molecular-Envelope Technology (MET) enkephalin formulation being developed for the management of acute and chronic pain, including pain associated with cancer, as well as post-traumatic stress disorder (PTSD) under the name PES200. MET technology is also used in AnQlar™, a candidate to inhibit viral replication caused by influenza or SARS-CoV-2. Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children, a rare pediatric disease. For more information, please visit www.virpaxpharma.com.

Virpax Pharmaceuticals Chairman and CEO Anthony Mack delivers a formal corporate overview, followed by a Q & A session moderated by Noble Capital Markets Senior Healthcare Services & Medical Devices Analyst Gregory Aurand.

News & Advanced Market Data on Virpax Pharmaceuticals: https://www.channelchek.com/company/VRPX


Leave A Reply

Your email address will not be published.